Standard

In Vivo Accelerator-Based Boron Neutron Capture Therapy for Spontaneous Tumors in Large Animals: Case Series. / Kanygin, Vladimir; Kichigin, Aleksandr; Zaboronok, Alexander и др.

в: Biology, Том 11, № 1, 138, 01.2022.

Результаты исследований: Научные публикации в периодических изданияхстатьяРецензирование

Harvard

APA

Vancouver

Kanygin V, Kichigin A, Zaboronok A, Kasatova A, Petrova E, Tsygankova A и др. In Vivo Accelerator-Based Boron Neutron Capture Therapy for Spontaneous Tumors in Large Animals: Case Series. Biology. 2022 янв.;11(1):138. doi: 10.3390/biology11010138

Author

Kanygin, Vladimir ; Kichigin, Aleksandr ; Zaboronok, Alexander и др. / In Vivo Accelerator-Based Boron Neutron Capture Therapy for Spontaneous Tumors in Large Animals: Case Series. в: Biology. 2022 ; Том 11, № 1.

BibTeX

@article{c22cb5a7fd804e1c9ee073f1b6e314b8,
title = "In Vivo Accelerator-Based Boron Neutron Capture Therapy for Spontaneous Tumors in Large Animals: Case Series",
abstract = "(1) Background: accelerator-based neutron sources are a new frontier for BNCT but many technical issues remain. We aimed to study such issues and results in larger-animal BNCT (cats and dogs) with naturally occurring, malignant tumors in different locations as an intermediate step in translating current research into clinical practice. (2) Methods: 10 pet cats and dogs with incurable, malignant tumors that had no treatment alternatives were included in this study. A tandem accelerator with vacuum insulation was used as a neutron source. As a boron-containing agent,10B-enriched sodium borocaptate (BSH) was used at a dose of 100 mg/kg. Animal condition as well as tumor progression/regression were monitored. (3) Results: regression of tumors in response to treatment, improvements in the overall clinical picture, and an increase in the estimated duration and quality of life were observed. Treatment-related toxicity was mild and reversible. (4) Conclusions: our study contributes to preparations for human BNCT clinical trials and suggests utility for veterinary oncology.",
keywords = "Accelerator-based neutron source, Boron neutron capture therapy, Malignant tumors, Veterinary medicine",
author = "Vladimir Kanygin and Aleksandr Kichigin and Alexander Zaboronok and Anna Kasatova and Elena Petrova and Alphiya Tsygankova and Evgenii Zavjalov and Mathis, {Bryan J.} and Sergey Taskaev",
note = "Funding Information: Funding: The neutron generation was supported by the RUSSIAN SCIENCE FOUNDATION, project No. 19-72-30005. Article processing charges were covered by the RUSSIAN FOUNDATION FOR BASIC RESEARCH, scientific project No. 18-29-01007. Publisher Copyright: {\textcopyright} 2022 by the authors. Licensee MDPI, Basel, Switzerland.",
year = "2022",
month = jan,
doi = "10.3390/biology11010138",
language = "English",
volume = "11",
journal = "Biology",
issn = "2079-7737",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "1",

}

RIS

TY - JOUR

T1 - In Vivo Accelerator-Based Boron Neutron Capture Therapy for Spontaneous Tumors in Large Animals: Case Series

AU - Kanygin, Vladimir

AU - Kichigin, Aleksandr

AU - Zaboronok, Alexander

AU - Kasatova, Anna

AU - Petrova, Elena

AU - Tsygankova, Alphiya

AU - Zavjalov, Evgenii

AU - Mathis, Bryan J.

AU - Taskaev, Sergey

N1 - Funding Information: Funding: The neutron generation was supported by the RUSSIAN SCIENCE FOUNDATION, project No. 19-72-30005. Article processing charges were covered by the RUSSIAN FOUNDATION FOR BASIC RESEARCH, scientific project No. 18-29-01007. Publisher Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland.

PY - 2022/1

Y1 - 2022/1

N2 - (1) Background: accelerator-based neutron sources are a new frontier for BNCT but many technical issues remain. We aimed to study such issues and results in larger-animal BNCT (cats and dogs) with naturally occurring, malignant tumors in different locations as an intermediate step in translating current research into clinical practice. (2) Methods: 10 pet cats and dogs with incurable, malignant tumors that had no treatment alternatives were included in this study. A tandem accelerator with vacuum insulation was used as a neutron source. As a boron-containing agent,10B-enriched sodium borocaptate (BSH) was used at a dose of 100 mg/kg. Animal condition as well as tumor progression/regression were monitored. (3) Results: regression of tumors in response to treatment, improvements in the overall clinical picture, and an increase in the estimated duration and quality of life were observed. Treatment-related toxicity was mild and reversible. (4) Conclusions: our study contributes to preparations for human BNCT clinical trials and suggests utility for veterinary oncology.

AB - (1) Background: accelerator-based neutron sources are a new frontier for BNCT but many technical issues remain. We aimed to study such issues and results in larger-animal BNCT (cats and dogs) with naturally occurring, malignant tumors in different locations as an intermediate step in translating current research into clinical practice. (2) Methods: 10 pet cats and dogs with incurable, malignant tumors that had no treatment alternatives were included in this study. A tandem accelerator with vacuum insulation was used as a neutron source. As a boron-containing agent,10B-enriched sodium borocaptate (BSH) was used at a dose of 100 mg/kg. Animal condition as well as tumor progression/regression were monitored. (3) Results: regression of tumors in response to treatment, improvements in the overall clinical picture, and an increase in the estimated duration and quality of life were observed. Treatment-related toxicity was mild and reversible. (4) Conclusions: our study contributes to preparations for human BNCT clinical trials and suggests utility for veterinary oncology.

KW - Accelerator-based neutron source

KW - Boron neutron capture therapy

KW - Malignant tumors

KW - Veterinary medicine

UR - http://www.scopus.com/inward/record.url?scp=85123263464&partnerID=8YFLogxK

UR - https://www.mendeley.com/catalogue/d2c690ff-71aa-3052-9dc9-2def5cbdbd51/

U2 - 10.3390/biology11010138

DO - 10.3390/biology11010138

M3 - Article

C2 - 35053138

AN - SCOPUS:85123263464

VL - 11

JO - Biology

JF - Biology

SN - 2079-7737

IS - 1

M1 - 138

ER -

ID: 35305098